Compare Medpace Holdings Inc (MEDP) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Marqeta Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Marqeta Inc trades at $18.11 (market cap $1.82B). The key difference: Medpace Holdings Inc is far larger — about 9.2× Marqeta Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Marqeta Inc for 44 Days on average.
| MEDP | MQ | |
|---|---|---|
Market Cap | $16.82B | $1.82B |
Volume | 223,093 | 1,126,466 |
Sector | Health | Technology |
52-Week High | $630.19 | $20.32 |
52-Week Low | $393.42 | $15.04 |
Typical Hold Time | 14 Days | 44 Days |
Enterprise Value | $16.44B | $1.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Marqeta (MQ) trades at $17.44, up 2.23% today, showing strong momentum after beating earnings expectations for three consecutive quarters. The stock displays a bullish technical outlook with positive moving average signals, though valuation metrics remain elevated with a P/E of 193.83. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight ongoing business expansion despite mixed analyst sentiment.
MQ presents a high-risk, high-reward opportunity with improving fundamentals but premium valuation. Revenue growth has recovered from 2024 lows, and cash flow turned positive in 2025. However, the stock trades above most analyst targets, and contract renewals in Q3 2026 create near-term uncertainty. Investors should weigh growth potential against valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
